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Abstract
This submission details work published between 1979 and 1989 into some of the 
metabolic consequences of diabetes and the management of chronic pain. The results of 
these studies are to be found in the 26 published research papers appended.
1. The metabolic consequences of diabetes: studies in this area are various but fall 
into several distinct sections, a) the use of cortisol creatinine ratio as a marker for nocturnal 
hypoglycaemic episodes, these studies looked at the possibility that the stress response to 
hypoglycaemia could be used to identify episodes of nocturnal hypoglycaemia in insulin 
treated diabetics, b) investigations of the phenomenon of chlorpropamide alcohol flushing. 
These studies were designed to investigate the possibility that the tendency of some non­
insulin dependent diabetic patients to flush when taking alcohol concurrently with 
chlorpropamide was important as a marker of their susceptibility to the long term 
complications of the disease, c) other studies involving the metabolic aspects of diabetic 
complications. The role of magnesium in glucose disposal; urinary albumin as a marker of 
renal disease; haemoglobin glycosylation and retinopathy; hormones in pregnancy.
2. The management of chronic pain: this work arose as a natural continuation of 
the work with cortisol as a marker for hypoglycaemic stress and looked at the stress 
response to other clinical interventions such as surgery and in subjects who experienced 
chronic pain and sought to discover how this might affect recovery from surgery and 
general patient well being. As a consequence of these studies a more general assessment 
was made of pituitary function before and after alcohol destruction of the pituitary as a 
treatment for the relief of chronic pain.
Much of the work required the development of new analytical rests for various 
analytes e.g. chlorpropamide, free insulin, insulin antibodies, plasma acetate and urinary 
albumin.
1.0 Summary
The publications contained within this portfolio represent original work undertaken between 
1979-1989 and in collaboration with clinical and scientist colleagues in the fields of 
diabetes and pain. The main theme is that of analysis of diabetes but with minor excursions 
into the area of the metabolic and endocrine responses to pain. During these collaborations 
my role was largely that of analytical scientist; devising original techniques and 
experimental designs, as well as evaluating and performing the analytical and experimental 
procedures necessary to support the research hypotheses, but also contributing to the 
evaluation and interpretation of results and writing of material for publication. The results 
of these studies contributed to the development of our understanding of some areas of both 
diabetes and pain, to the improvement and development of analytical techniques for their 
study, and to the management of patient care.
2.0 Unrecognised Nocturnal Hypoglycaemia.
Before the discovery of insulin by Banting and Best in 1921 diabetes mellitus was invariably 
fatal, sufferers rarely surviving beyond early adulthood. Once universal insulin treatment had 
removed the immediate spectre of mortality it became apparent that insulin treatment alone was 
not a cure for the disease but the intermittent nature of insulin delivery would itself lead to 
unique metabolic consequences resulting in an increased mortality and morbidity associated with 
diabetes. In particular, insulin-dependent diabetics would often suffer from nephropathy, 
neuropathy, and a range of micro- and macro-vascular complications. It has now become an 
accepted aim of insulin treatment should be to establish 'good glycaemic control' and that control 
of the blood glucose to near normal levels should reduce the incidence of diabetic complications. 
Long term studies have subsequently confirmed the veracity of this belief. An unfortunate 
consequence of the maintenance of good glycaemic control is that, in the absence of normal 
feedback control, the insulin dose required to reduce the glucose to normal may under some 
circumstances be in excess thus causing an increase in hypoglycaemic episodes1. Indeed,
iiypugiycaemia muuceu uy insulin neaimein may oe me most irequenuy ODServea meiaooilC 
emergency2.
In 1979, before blood glucose measurement at home was possible, it was usual to 
determine insulin dosage via a combination of patient records of the qualitative assessment of 
morning urine glucose and random blood glucose measurements taken in a diabetic clinic. When 
the diabetes seemed uncontrollable patients were hospitalised so that monitoring of the blood 
glucose during the day could be carried out. Clearly undertreatment with insulin will result in a 
raised blood glucose level especially during the overnight period when individuals are sleeping. 
As early as 1959, however, Somogyi3 had advanced the theory that insulin overtreatment, 
causing unrecognised nocturnal hypoglycaemia, could result in the secretion of counter- 
regulatory hormones, such as adrenaline and cortisol, whose effects would oppose the actions of 
insulin and mobilise glucose stores such that the fasting glucose level in a patient upon waking 
would be raised. Clearly this posed a serious clinical dilemma since if this theory was correct 
both undertreatment and overtreatment with insulin could result in a raised fasting blood glucose 
making decisions regarding treatment changes most difficult.
This was the stimulus for a group of us to begin to consider ways in which it might be 
possible to determine if a raised fasting blood glucose could be easily attributed to either over or 
undertreatment with insulin. Insulin lowers blood glucose by inhibition of glycogenolysis and by 
stimulating the uptake of glucose by the peripheral tissues. As the blood glucose falls other 
glucose regulating hormones, notably glucagon and adrenaline, are released to 'balance' the effect 
of insulin and restore the blood glucose, these effects being so efficient as to maintain the fasting 
blood glucose within narrow limits. Both glucagon and adrenaline have an acute effect on the 
maintenance of the blood glucose. Where hypoglycaemia is prolonged both cortisol and growth 
hormone are also secreted and contribute to the insulin resistance which is seen after 
hypoglycaemic episodes 4.
Thus the hypothesis was proposed that in response to the hypoglycaemia caused by 
insulin overtreatment, counter-regulatory hormones to be released, and thus their measurement 
on waking may be an indication of the mode of the nocturnal hypoglycaemia. In order to be 
clinically useful the determination of insulin overtreatment would have to be sufficiently rapid
io anuw iur immeuiaie cnanges in ireauneni ana, lor paueni acceptance, snouia aiso oe 
minimally invasive. At the time we began to consider this problem the measurement of 
hormones by immunoassay was still very much in its infancy and the measurement of glucagon 
and adrenaline was impractical whilst growth hormone assays required overnight incubations and 
therefore would not give the required information in adequate time. This left cortisol as a 
hormone for consideration. Cortisol is usually present in blood associated with the transport 
protein, cortisol binding globulin (CBG). At that time the measurement of plasma cortisol still 
required extraction from binding proteins before complex fluorimetric analysis thus making the 
assays lengthy and invasive if blood samples were to be used. It was, therefore, decided to try to 
use the measurement of cortisol in a randomly sampled morning urine, collection of which would 
be minimally invasive, and where measurements would be unaffected by protein binding. The 
technique chosen initially was the competitive protein binding method devised by Beardwell and 
Burke5 utilising pregnancy serum as a source of binding protein and tritium-labelled cortisol as 
the tracer. The method was improved by altering the bound/free separation step and omitting the 
extraction of urines with dichloromethane. The assay was validated against the existing 
fluorimetric method with extraction. As a result of these ideas three studies were performed and 
subsequently published.
1. A preliminary study (#3) was performed to establish whether excretion of cortisol 
overnight could be used to demonstrate a nocturnal hypoglycaemic event. Because the samples 
were random urines it was decided to express the results as a ratio with the urinary creatinine in 
order to account for varying diuresis. The cortisol to creatinine ratio in an early morning urine 
sample was compared in four groups of patients; healthy subjects, non-diabetic hospital patients, 
diabetics without presumptive hypoglycaemia, and diabetics in whom hypoglycaemia was 
strongly suspected. In this study there was a clear distinction between the healthy subjects, the 
hospitalised non-diabetics, the symptom-free diabetics, and those with frank hypoglycaemia, 
allowing the establishment of a unitless ratio with a cut off level of >55 x IO6 as indicative of a 
hypoglycaemic event.
2. The second study (#4) reported the use of the cortisol/creatinine ratio in the outpatient 
clinic. The results supported the argument regarding the prevalence of nocturnal hypoglycaemia
in me uiaucue pupumuuii. jL/umig me siuuy ui oz pauenis auenuing me aiaoenc cnnic ana 
encompassing 200 early morning urines, 26 had cortisol/creatinine ratio in excess of 55 x 10’6 
giving a prevalence of 26% for nocturnal hypoglycaemia, a figure which was similar to others 
reported at that time.
3. The third paper (#5) considered the use of the cortisol/creatinine ratio to aid in the 
detection of unrecognised nocturnal hypoglycaemia and in the optimisation of insulin dose in a 
group of diabetic in patients. The ratio was used to optimise the insulin dose such that if the 
fasting glucose was above 7 mmol b1 the long acting insulin was increased, unless the 
cortisol/creatinine ratio was above 55 x IO6 in which case it was reduced. Of the 43 patients 
studied 9 were stabilised by insulin reduction of insulin dose whilst 34 were stabilised by 
increasing the insulin dose.
It is reasonable to suggest that the use of cortisol/creatinine ratio to determine nocturnal 
hypoglycaemia represented an original contribution to the debate concerning nocturnal 
hypoglycaemia and the Somogyi effect. Other workers reported variable experiences with the 
test, some found it useful 6>7=8, others not 9>10. Since this time, however, considerable 
sophisticated work has been performed such that the scientific concepts underlying the Somogyi 
effect have been called into question. Whilst there is undoubtedly a rise in glucose between 5 am 
and 8 am this is caused by the normal diurnal changes in growth hormone secretion which occur 
irrespective of nocturnal hypoglycaemia. When nocturnal hypoglycaemia does occur, although 
there is a counter-regulatory response to hypoglycaemia in diabetics, it is insufficient to cause a 
rebound elevation of glucose in the presence of insulin. Further, it has also been shown that the 
counterregulatory response to hypoglycaemia is impaired in patients with diabetes11 . This has 
been shown mainly to influence glucagon and adrenalin with disagreement as to the effect of 
circulating insulin level on the cortisol response to hypoglycaemia. However, a decreased 
response of cortisol to CRF at elevated levels of insulin has been shown for healthy subjects12 . 
Any effect of increased insulin level is likely to be further exacerbated by the presence of 
circulating insulin antibodies which act as a resevoir for insulin.
iNonemeiess anempts io maintain normogiycaemia mean tnat tne diagnosis ot nocturnal 
hypoglycaemia still represents a serious clinical problem. The existence or otherwise of the 
Somogyi effect is a subject around which there is still considerable debate 13.
3.0 The endocrine response to pain.
As a result of the above studies a strong collaboration was established with members of 
the Oxford Regional Pain Relief Unit who were interested in the possible endocrine and 
metabolic responses to surgery and to pain. This collaboration resulted in four publications 
(#6,#8,#9,#13) between 1981 and 1983. In each of these studies my contribution involved the 
design and planning of experiments, liason with the clinical team, collection of samples, storage 
and handling of samples and data, the conduct of the laboratory investigations, analysis of data 
and the production and presentation of the finished work.
It had been recognised that surgical stress resulted in some well defined metabolic and 
hormonal responses which were characterised by altered carbohydrate metabolism, net protein 
loss and lipolysis. It had been suggested that improved post-surgical morbidity could be 
achieved by reducing the stress response to the surgery and strategies to control postoperative 
pain were designed with this end in view. These studies, however, had been mainly concentrated 
on gynaecological procedures and had neglected to consider the possibility of a difference related 
to sex. The first study (#6) aimed to consider the endocrine and metabolic response to 
anaesthesia and surgery in subjects undergoing total hip replacement. This study looked at the 
metabolic and endocrine response (as determined by the plasma glucose, cortisol and prolactin), 
during and following surgery in 12 men and 8 women treated with the synthetic opiate, 
buprenorphine, immediately before and 3 hours post operation.
A stress response to the operation was clearly evident with all three measured substances 
showing a post surgical elevation. What was interesting was the finding that there were 
significant differences in the response for men compared with those in women. Men showed a 
fall in cortisol after the second dose of buprenorphine while women had a greater rise in prolactin 
than the men. Attempts to produce stress free surgery still continue today. The current debate 
mainly concerns the possible benefits of epidural analgesia14’15 and patient controlled analgesia16 
in reducing the stress response to surgery.
we continued mis nne 01 enquiry, aioeu some years later, oy examining wnetner me 
cortisol/creatinine ratio technique we had devised earlier could be used to observe a stress 
response induced by pain alone. (#13). A total of 67 patients attending the Pain Relief Unit were 
studied compared with a control group comprising 33 subjects who were either laboratory staff 
or convalescent in-patients at the Radcliffe Infirmary, Oxford. The subjects had pain from a 
variety of causes and were receiving a number of therapies. Of these 31% showed a raised 
cortisol /creatinine ratio. None of these could be related to pain score, cause of pain or drug 
therapy. Given the relatively small numbers and many variables this is perhaps not so surprising. 
What is important, however, is that this study contributed to the debate that pain itself could be 
considered a stress and that the treatment of pain should also be aimed at reducing the hormonal 
component of the stress response. The debate as to how best to modify the stress response to 
pain continues today.17
This interest in the endocrine responses to stimuli led to my development of a number of 
immunoassays for pituitary hormones, especially growth hormone, lutenising hormone, follicle 
stimulating hormone and thyroid stimulating hormone. A collaboration then evolved between 
myself and a group of surgeons who were performing hypophysectomy for the relief of terminal 
cancer pain. It was known that alcohol ablation of the pituitary could relieve cancer pain in 
about 70% of patients18 but the mechanism was unknown19. The degree of pituitary functional 
loss, and its effects, were also unknown at this time. Thus, it was decided to study the effect of 
hypophysectomy on pituitary function. Pituitary function was tested before; and 6 and 12 weeks 
after, pituitary ablation, by measuring the response at 30 minute intervals for 2 hours to releasing 
hormone stimulation and hypoglycaemic stress. The results showed again that pain relief was 
achieved, but that destruction of the pituitary was variable. Pain relief was not related to loss of 
any particular hormone or to the degree of pituitary destruction. The mechanism for this effect 
remains controversial20.
4.0 Chlorpropamide Alcohol Flushing
Non-insulin dependent diabetic patients have been prescribed oral hypoglycaemic agents 
for over 30 years and chlorpropamide has always been one of the most popular of these agents21. 
Chlorpropamide treatment has always been associated with certain side effects; particularly
nyponairaemia ana nypogiycaemia, especially in me eiaeriy^, nypertension,iJ ana an unusual 
reaction which is characterised by an embarrassing facial flushing after alcohol ingestion 
(Chlorpropamide Alcohol Flushing, CPAF) not unlike that seen with disulfiram. This flushing 
phenomenon was studied extensively during the 1980's as possibly genetically derived and thus a 
potential marker for subsequent diabetic complications. It is no longer considered to be of any 
pathophysiological significance but nonetheless engendered considerable debate at the time. Dr 
Rowan Hillson was particularly interested in this phenomenon and I was approached with a view 
to setting up a team to study the mechanism underlying the facial flushing. This collaboration 
was to yield three publications over the next few years (#11, #12, #24). Dr Hillson had developed 
a technique for measuring cheek temperature rise in response to a measured dose of alcohol. 
Although we were able to relate this to the dose of the drug we particularly wanted to try to relate 
the cheek temperature rise to the circulating level of the drug. My first assay for chlorpropamide 
involved solvent extraction from serum followed by methylation using diazomethane and gas- 
liquid chromatography (GLC) with flame ionisation detection. This was quite successful and the 
first studies were performed using this assay. It was , however, quite time consuming and the 
methylation step meant that we often had poor recoveries. The introduction into the laboratory 
of a high performance liquid chromatograph allowed the development of a new assay which 
permitted direct measurement of chlorpropamide on this instrument using UV absorption. This 
eliminated the requirement for derivatisation in the GLC method, and at the same time enabled 
the assay of the drug to be determined with greater speed. Subsequent interest in the possible 
role of acetaldehyde and aldehyde dehydrogenase in this phenomenon led to my development of 
assays for erythrocyte chlorpropamide and for aldehyde dehydrogenase within the red cell. As 
previously my role in this group extended also to planning (and often to the performance) of 
experiments, collection and storage of samples, collation of data and the writing of publications.
The first publication (#11) reported the findings from a cross over study involving six 
subjects given either chlorpropamide or placebo. Red cell aldehyde dehydrogenase activity failed 
to correlate with plasma chlorpropamide or with the flushing phenomenon. This finding was 
confirmed during a more extensive study (#24) involving 21 subjects on long term 
chlorpropamide therapy. The attempt to link the flushing phenomenon to the activity of
aiuenyue uenyurogenase was logical since 11 was Known mai levels 01 aceiaiaenyae were raisea 
in those who exhibited flushing. In retrospect, however, these findings are can now be 
understood since this phenomenon is mediated via inhibition of hepatic aldehyde dehydrogenase 
by an as yet unknown metabolite of chlorpropamide24. The other publication (#12) reported the 
observations in two groups; one which had noted flushing and one which had not. The extent of 
the facial flush as measured by cheek temperature rise, was correlated to the plasma 
chlorpropamide level (irrespective of group) and to the daily dose of the drug. Thus the 
hypothesis that CPAF was a marker for diabetic complications would seem to have been 
something of a confounder with all subjects, even non-diabetics25, exhibiting the phenomenon to 
some degree.
5.0 The Oxford Prospective Study.
During the time at the Sheikh Rashid Diabetes Unit there was an ongoing prospective 
study of non-insulin dependent diabetes (NIDDM) for which I became responsible for the day to 
day organisation of samples and assays. This study aimed to look prospectively at patients 
diagnosed with NIDDM between 1973 and 1976. The diagnostic criteria for entry to the trial 
were glucose disposal rate constant (KG) < 1.2 during a 20 g/m2 body surface intravenous 
glucose tolerance test, or a preceding blood glucose > 8.5 mmol F . Many clinical and 
biochemical parameters (e.g. KG, glucose, Body Mass Index, blood pressure, glycerol, lactate, 
insulin, ECG and vibratory sensory threshold) were measured at diagnosis and 3 and 5 years post 
hoc in order to assess their possible contributions to the morbidity associated with the disease. 
Interim studies and reports were published from these studies using this valuable database.
5.1 Magnesium and diabetes.
During the early 1980's there was increasing interest in the role of certain metal ions in 
the development of diabetes and its complications. In particular, magnesium had been shown to 
be associated with impared glucose disposition, retinopathy, platelet dysfunction, and 
hypertension. Thus, Dr Nick Ward at the Imperial College Reactor Centre was invited to 
collaborate in a study of the role of metal ions in diabetes using the existing sample database.. 
The attraction of this collaboration was that Dr Ward used the technique of neutron activation 
analysis, a method capable of the determination of a large number of ions from the same sample.
rrom me analysis me resuns couiu oe iea mio me aaiaoase ana associations sougnt, using 
multiple linear regression analysis, between the various clinical and biochemical parameters. My 
role in this study involved being responsible for the sample collections, integrity of samples, 
collation of data and various biochemical analyses. I was also required to validate the elemental 
analysis technique. Because Neutron Activation Analysis was a specialised technique which had 
not been used in this area previously it was necessary to check the associations found using more 
traditional techniques. Thus, I set up atomic absorption spectrophotometric techniques for 
several of the atoms of interest, especially magnesium, calcium, vanadium, aluminium and zinc, 
using liquid aspiration and graphite furnace techniques. This was necessary in order to validate 
the results found by neutron activation analysis. A strong correlation was established between 
magnesium and glucose disposal which became the basis for publication #14.
In this study 32 insulin treated and 55 non-insulin treated as well as 30 non diabetic 
subjects were investigated. No differences were found in plasma magnesium between diabetic 
and non-diabetic subjects taken together. However, when analysed according to those taking 
insulin and those who were not, it was found that those who received insulin had lower 
magnesium, while those who did not, had higher magnesium than the controls. Plasma 
magnesium was found to be inversely related to both glucose and haemoglobin A1C (an 
integrated index of long term glucose control) and directly related to the rate constant, KG, even 
allowing for the previous relationship to glucose. These findings have recently been confirmed26.
Serum contains only 0.3% of the total body magnesium. Various methods have been 
used to assess magnesium status; erythrocyte magnesium, leucocyte magnesium, 24 hour urinary 
magnesium excretion as well as, more recently, methods based on ion-selective electrode 
assessment of ionised magnesium and methods based on nuclear magnetic resonance27. A recent 
review28 confirms these findings and notes that hyperglycaemia appears to induce 
hypomagnesaemia via osmotic diuresis. The study raised the question of the possible benefits of 
magnesium supplementation, but the advantages of this are still unresolved29’30
5.2 Mortal factors in NIDDM
The second publication to arise from the Oxford Prospective Study (#17) related to 
factors which predicted death five years from diagnosis. It reflects a substantial volume of data
collected over many years witn signmcant contributions Irom several individuals including 
myself. The paper discusses the outcomes of 214 patients at five years post diagnosis of 
NIDDM and established, by a stepwise logistic regression proceedure, those factors which 
predispose to death and an overall prediction factor which may be used to target those most at 
risk. Five factors were determined; long duration of symptoms and a) increased glucose 
intolerance b) higher systolic blood pressure, c) less obesity, d) higher blood glycerol; all judged 
at one year after diagnosis. Using the predictive mortality index gave a sensitivity of 90% and a 
specificity of 83%. These findings were confirmed recently at ten year review 31>32 and extended 
in that the two major associations (glucose tolerance and blood pressure) appeared to form two 
independent interrelated groups: a metabolic group and one associated with 'degenerative 
conditions'. The search to identify risk factors and assess their contributions to disease continues 
today.33’34’35
5.3 Retinopathy and glycosylated haemoglobin (HbA)
A major complication of diabetes is the development of retinopathy that manifests as tiny 
microvascular aneurysms on the retina of the eye which can give rise to blindness. Part of the 
Oxford Prospective Study involved a collaboration with members of the Oxford Eye Hospital to 
monitor retinopathy in study subjects and to identify any predisposing factors. It had been 
recognised for some time that there was a relationship between the prevalence of retinopathy and 
glycaemic status as judged by fasting blood glucose measurements. The use of glycosylated 
haemoglobin measurements as a long term index of glycaemic control afforded the potential for a 
more useful index. This enabled the comparison of prevalence and progression of retinopathy to 
be related to glycosylated haemoglobin within the study. For this reason we set about 
developing a method for the routine assay of HbA Several methods had been described for this 
measurement; ion-exchange chromatography, affinity chromatography on boronic acid gels, iso­
electric focussing and agarose gel electrophoresis utilising the electroendosmotic flow principle. 
Each method was developed and validated within our laboratory. I found that the agarose gel 
technique was offered the best analytical and clinical performance. At this stage we prepared our 
own gel plates and buffer systems and despite the introduction of commercial systems for this 
analysis we continued to use our own method for the duration of this study.
i ne paper rrom mis worn j ) snowea max, wnnsi me prevalence 01 retmopamy may oe
related to glycaemic control, once disease is established, progression of the disease is then 
unrelated to glycaemic control. This was very much in accord with the observation that 
scrupulous glycaemic control did not improve established retinopathy. A small but significant 
relationship was observed between the progression of retinopathy and the level of non-esterified 
fatty acids.
Recent studies continue to show glycaemic control as central to the development of 
retinopathy in both IDDM and NIDDM36, although some studies show that progression is also 
related to the level of hyperglycaemia37. It is possible that the variable progression to retinopathy 
seen in individuals has a genetic component with the finding of a relationship to the 
immunoglobulin Gm allotype.38
6.0 The measurement of Free Insulin
Insulin treatment has been the obligatory treatment for juvenile onset diabetes since its 
first introduction in 1921. Until the introduction of recombinant human insulin, almost all of the 
insulin used has been obtained from either porcine or bovine pancreas. In 1944 Lowell39 
reported the presence of antibody -like insulin neutralising factors in serum. That these factors 
were indeed antibodies was confirmed by Yalow and Berson and co-workers40. Such antibodies 
are to be found in the serum of almost all insulin treated diabetics within a few weeks of the 
commencement of insulin treatment. Theoretically insulin antibodies could give rise to several 
deleterious effects in-vivo; among them insulin resistance, hypoglycaemia due the inappropriate 
release of insulin and vascular complications due to circulating immune complexes. In practice, 
however, their presence seems to have few discernible clinical effects. Plasma insulin levels in 
diabetic patients previously treated with insulin cannot be measured by conventional 
immunoassay methods because of the presence of the human anti-insulin antibodies in the 
plasma interfere with the antibodies in the assay. These endogenous antibodies can combine 
with the added labelled insulin and interfere between the binding of labelled and unlabelled 
ligand. At the Sheikh Rashid Unit we were anxious to develop methods suitable for the 
measurement of the free biologically active insulin and I was fortunate to be allowed to spend 
some time at the Novo Institute in Copenhagen learning the polyethylene glycol (PEG)
precipitation lecimique ior assay 01 iree insulin, in is recnmque invoivea me precipnauon 01 
anti-insulin antibody with attendant insulin thus leaving the free unbound insulin in the 
supernatant fluid following centrifugation. Once the method was introduced into our laboratory I 
became intrigued why the precipitated insulin antibody should continue to bind insulin. I 
reasoned that the PEG precipitation procedure should destroy the tertiary structure of the insulin 
antibody and thus the binding site for insulin. I decided to apply the method of Steady State Gel 
Filtration (SSGF) to this problem. SSGF had been developed by Burke 41 for the measurement 
of free steroid hormones and seemed equally applicable to this problem.42 The results of this 
study were submitted as part contribution to the degree of MSc 43. Two other publications arose 
as a result of my work in this area (#1, #2), the first formed a chapter in "Methods in Diabetes 
Research" where the current techniques for free insulin measurement were described and the 
second was an invited review article on the effects of insulin antibodies and the various methods 
for the measurement of free insulin.
7.0 Analytical Publications
This section outlines four different publications which may be described as being purely 
analytical topics. In each case my role was related to assay and experimental design, data 
interpretation and to the writing of the final publication.
7.1 Thyroxine
This paper #10, describes a simple method developed at our laboratory at the Radcliffe Infirmary 
for the analysis of thyroxine by radioimmunoassay. At this time (1982) commercial assay kits 
were becoming freely available and whilst previously immunoassay had been the province of 
larger institutions with our expertise the advent of commercial reagents offered the opportunity 
for smaller laboratories to perform what were hitherto rather specialist tests. There was 
considerable debate as to the merits of commercial reagents especially in terms of cost. This 
paper aimed to demonstrate that analytically sound, cost effective assays could be created simply 
using commercially available individual components rather than purchasing the reagents in 
expensive kit form.
/.Zr urinary aiuuiinii
Around 1982 Viberti44 reported that the finding of low concentrations of albumin 
(microalbuminuria) in the urine of diabetic subjects could act as a marker of subsequent renal 
complications. In order to investigate this observation for our own patients I designed a 
radioimmunoassay for albumin in urine which we used for various subsequent studies and then 
routinely in the management of patients. We collaborated with a group from the Institute of 
Urology in London who wanted to set up an assay for microalbumin but who did not have access 
to radioimmunoassay equipment. We decided to develop an electroimmunoassay in order to 
retain the benefits imparted by the antibody technology without the problems associated with 
radioimmunoassay. This novel approach had two main drawbacks; electroimmunoassay was 
traditionally slow, insensitive and is less suited to large sample numbers. A more useful assay 
was, however, designed, which compared favourably with our existing in house assay and which 
offered a new approach for laboratories with a small diabetic population who wished to offer this 
measurement.
7.3 Plasma Acetate
It was common practice at the Sheikh Rashid Diabetes Unit to measure various intermediary 
metabolites during studies on diabetic subjects, in particular the free fatty acids and ketone 
bodies. We were interested in the measurement of acetate for several reasons. Whether the high 
turnover of fatty acids found in diabetic subjects was likely to cause an increase in acetate. 
Because of the relationship of acetate to alcohol metabolism, and thus CPAF. And what effect 
the higher circulating levels of glucose found in diabetic subjects would have on the level of 
circulating acetate. There were at that time no simple methods available for the measurement of 
acetate in plasma. The extant methods were either complex enzymatic methods or gas liquid 
chromatography. The recent commercial availability of the enzyme acetate kinase allowed us 
to modify the method of Trivin 45 to a relatively simple coupled assay system and to adapt the 
method for analysis by centrifugal analyser in order to facilitate a high throughput of samples. 
We realised early on that the commercial preparations of acetate kinase could be contaminated 
by hexokinase and would need to be checked before use. My studies showed that indeed, acetate 
levels were higher in diabetic subjects compared to non-diabetics. Furthermore acetate levels
were correlated io glucose, lacxaie ana acetoacetate levels, umer man observations in rats, HO tms 
was probably the first report of increased plasma acetate in diabetic subjects. This method was 
subsequently the mainstay of several studies which increased our knowledge regarding the 
metabolism of acetate in diabetes. 47-52 
7.4 Insulin and haemolysis
It had been reported that haemolysis affected insulin assay when charcoal was used as the 
mechanism for the separation of bound from free label. A group of us involved in measuring 
insulin were interested whether this was an observation unique to the separation method or one 
that was general to measurement of insulin. The paper (#22) reports the results of a study in 
which samples split and then deliberately haemolysed were assayed by either using charcoal 
separation or separation using a double antibody technique. C-peptide was also measured. The 
study clearly showed that a reduction in immunoreactive insulin occurred independently of the 
assay method, and that C-peptide was not so affected. These findings were of importance to 
anyone involved in the analysis of plasma insulin.
8.0 Miscellaneous.
This section comprises three publications which represent collaborations with other research 
groups.
8.1 Albumin Creatinine Ratio.
This publication (#18) was a collaboration between myself and members of the John Radcliffe 
Hospital Department of Paediatrics and Northampton General Hospital. My contribution was to 
provide the laboratory analyses, particulary the urinary albumin, to be responsible for the 
samples and liason during the exercise testing. I was involved in the data collection and 
contributed to its interpretation and to the final construction of the paper. Since it was known 
that whilst morphological changes could be observed in the kidneys of virtually all diabetics, but 
that only about 35% would subsequently progress to clinical nephropathy, the measurement of 
'microalbuminuria' was seen as a possible marker for this subgroup. Furthermore it had been 
suggested that strict metabolic control could delay progression to nephropathy in this group.
Thus the aims of this experiement were to see if exercise could unmask latent glomerular damage 
in children before overt microalbuminuria appeared and thus define the at risk subgroup at the
earnest possioie time post aiagnosis. iviemoers 01 me university uepartment or raeaiatncs 
performed a standardised exercise test on 40 children with IDDM and 21 non-diabetic similar 
children. Samples were collected pre and post exercise. The data was expressed either as 
Albumin Excretion Rate (AER) or as albumin/creatinine ratio. There was no difference between 
the diabetic and control groups before exercise but a quarter of the diabetic subjects showed an 
increased albumin excretion post exercise when compared to the non-diabetics. None of the 25% 
of diabetic subjects would have been characterised as abnormal by previously established 
criteria. Longer term studies53 have confirmed these immediate post exercise findings but failed 
to find an increase in prediction of future renal damage.
8.2 Water Balence in the Elderly (#21).
Reduced renal excretion of water in the elderly leading to oedema and hyponatraemia 
represents a serious clinical problem. Dr Martin Crowe was particularly interested in this 
problem and assembled a group to perform a study of the problem. The aim of the study was to 
investigate the effects of age on thirst, vasopressin and renal responses to an oral water load and 
to determine whether the ability to excrete excess water is impaired in the elderly. My 
involvement in this study extended from planning and study design, the measurement of osmolar, 
creatinine and free water clearances, and writing of the published article. Six elderly water 
replete men were compared to two control groups of 6 water replete and six water deprived 
young men. The study clearly demonstrated a defective renal water excretion and thirst in 
elderly men compared to young men. This study extended the work of Lindeman54 who 
examined the effects of age on free water clearance during maximal water diuresis but who was 
unable to measure plasma sodium, osmolality or vasopressin. These were important findings 
which increased our knowledge of water balence in the elderly and had significant outcomes in 
terms of patient care.
8.3 Hormonal changes in Diabetic Pregnancy (#20)
Pregnancy poses a considerable diabetogenic stress. Since many of the metabolic 
changes in pregnancy could be reproduced by administration of growth hormone (GH) it was 
decided to study the relationship between GH and Human Placental Lactogen (HPL) and the
development 01 uiaoeue complications during pregnancy, j  groups 01 suojecis were studied 
during 2nd and 3rd trimester until post-natel examination. 14 were non-diabetic, 15 insulin- 
dependent and 8 gestational diabetic. I was involved in all aspects of this study, particularly the 
evaluation of the HPL assay and the checking of antibody specificities between the closely 
related GH and HPL. I was responsible for the performance of the other assays (Urinary 
albumin, glycosylated Hb etc.) for the maintenance of the samples and for the collection of data. 
The study found no increase in tissue damage amonst the subjects studied. The urinary albumin 
rose in the immediate post-natel period in the IDDM group. Systolic blood pressure also rose in 
the 3rd trimester and pre-delivery in both the diabetic groups. This was the first study to show 
that diabetic subjects had higher GH levels than controls during pregnancy. Much work has 
continued in this area. It is now recognised that the placenta also secretes GH55 and that this may 
regulate the secretion of maternal IgF-156 during pregnancy. It has further been suggested that 
the diabetogenic stress associated by GH may in fact be due to a 17-kilodalton fragment (hGH)- 
(44-191) rather than intact GH57.
9.0 Learned Societies
During the period covered in this submission I was an active member of both the Medical 
Research Society and the British Diabetic Association (I remain a member of the MRS). During 
this time I attended a number of National and International Scientific Conferences to present 
papers and posters. Publications #7,15, 25, 26 and others (see Appendix 1) are submitted as 
evidence of an active contribution to the scientific community.
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